Identification of I1171N resistance mutation in ALK-positive non-small-cell lung cancer tumor sample and circulating tumor DNA

Lung Cancer

Volumn 99, Issue , 2016, Pages 38-40

  Johnson, Alison C ^a   Dô, Pascal ^a   Richard, Nicolas ^b   Dubos, Catherine ^a   Michels, Jean Jacques ^a   Bonneau, Jessica ^b   Gervais, Radj ^a  

^a CENTRE FRANÇOIS BACLESSE   (France)

^b CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

ALK; Circulating tumor DNA; Crizotinib; Non small cell lung cancer; Resistance mutation

Indexed keywords

ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; ASPARAGINE; BEVACIZUMAB; CERITINIB; CHLOROPLAST DNA; CRIZOTINIB; DOCETAXEL; ISOLEUCINE; PEMBROLIZUMAB; PEMETREXED; PLATINUM; ANTINEOPLASTIC AGENT; CIRCULATING TUMOR DNA; PROTEIN TYROSINE KINASE;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CASE REPORT; COMPASSIONATE USE; CONTROLLED STUDY; DISEASE COURSE; DNA SEQUENCE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; KIDNEY FAILURE; LIVER BIOPSY; LIVER METASTASIS; LUNG ADENOCARCINOMA; LYMPH NODE METASTASIS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NEXT GENERATION SEQUENCING; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEREOTACTIC RADIOSURGERY; TUMOR BIOPSY; ALLELE; CANCER STAGING; CODON; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE; FATALITY; GENETICS; LUNG TUMOR; METASTASIS; MUTATION; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; X-RAY COMPUTED TOMOGRAPHY;

ALLELES; AMINO ACID SUBSTITUTION; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CIRCULATING TUMOR DNA; CODON; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; FATAL OUTCOME; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; NEOPLASM STAGING; RECEPTOR PROTEIN-TYROSINE KINASES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84975840907     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.06.010     Document Type: Article

References (13)

1. [1] Steuer, C.E., Ramalingam, S.S., ALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment options. Cancer 120 (2014), 2392–2402.
2. [2] Shaw, A.T., Kim, D.W., Nakagawa, K., Seto, T., Crino, L., Ahn, M.J., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 368 (2013), 2385–2394.
3. [3] Shaw, A.T., Kim, D.W., Mehra, R., Tan, D.S., Felip, E., Chow, L.Q., et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N. Engl. J. Med. 370 (2014), 1189–1197.
4. [4] Janoueix-Lerosey, I., Lequin, D., Brugieres, L., Ribeiro, A., de Pontual, L., Combaret, V., et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455 (2008), 967–970.
5. [5] Mosse, Y.P., Laudenslager, M., Longo, L., Cole, K.A., Wood, A., Attiyeh, E.F., et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455 (2008), 930–935.
6. [6] Ou, S.H., Klempner, S.J., Greenbowe, J.R., Azada, M., Schrock, A.B., Ali, S.M., et al. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to alectinib. J. Thorac. Oncol. 9 (2014), 1821–1825.
7. [7] Toyokawa, G., Hirai, F., Inamasu, E., Yoshida, T., Nosaki, K., Takenaka, T., et al. Secondary mutations at I1171 in the ALK gene confer resistance to both crizotinib and alectinib. J. Thorac. Oncol. 9 (2014), e86–7.
8. [8] Ou, S.H., Greenbowe, J., Khan, Z.U., Azada, M.C., Ross, J.S., Stevens, P.J., et al. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib. Lung Cancer 88 (2015), 231–234.
9. [9] Combaret, V., Iacono, I., Bellini, A., Brejon, S., Bernard, V., Marabelle, A., et al. Detection of tumor ALK status in neuroblastoma patients using peripheral blood. Cancer Med. 4 (2015), 540–550.
10. [10] Suda, K., Onozato, R., Yatabe, Y., Mitsudomi, T., EGFR T790M mutation: a double role in lung cancer cell survival?. J. Thorac. Oncol. 4 (2009), 1–4.
11. [11] Imamura, F., Uchida, J., Kukita, Y., Kumagai, T., Nishino, K., Inoue, T., et al. Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer. Lung Cancer 94 (2016), 68–73.
12. [12] Zheng, D., Ye, X., Zhang, M.Z., Sun, Y., Wang, J.Y., Ni, J., et al. Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. Sci. Rep., 6, 2016, 20913.
13. [13] Chan, K.C., Jiang, P., Zheng, Y.W., Liao, G.J., Sun, H., Wong, J., et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin. Chem. 59 (2013), 211–224.